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criteria were removed from the cohort. Demographic factors, wound heal-
ing, amputation rates, and mortality were obtained and analyzed in relation
to the initial APs and TPs. Outcomes were measured using Kaplan-Meier
life-table analysis and Cox proportional hazards models.
Results: CLI criteria were identiﬁed in 443 limbs of 381 patients. Af-
ter revascularization, 98 limbs with AP or TP, or both, improved to
>70 mm Hg and 50 mm Hg were removed from the study cohort. In
45 limbs, patients did not respond to the intial revascularization and their
APs or TPs, or both, remained within CLI criteria. These limbs remained
in the patient cohort, yielding a ﬁnal group of 296 patients and 345 limbs.
Mean follow-up time was 2.0 years. In the entire patient cohort, limb loss
occurred in 24% at 1 year and in 31% at 3 years. Mortality was 32% at
1 year and 56% at 3 years. Amputation-free survival was 54% at 1 year
and 28% at 3 years. Lower TPs were associated with a signiﬁcantly higher
incidence of amputation. Among the 85 with an initial TP #10 mm Hg,
limb loss occurred in 46% at 1 year and in 60% at 3 years. This limb loss
was signiﬁcantly greater than limb loss of 18% at 3 years among the 115
with a TP of 31 to 50 mm Hg (P < .001, Fig). Amputation-free survival
in patients with a TP #10 mm Hg was 8% at 3 years.
Conclusions: CLI is associated with a high mortality, but not all pa-
tients with currently deﬁned hemodynamic criteria for CLI are at high risk
of limb loss. Patients with a TP between 31 and 50 mm Hg (41% of the
cohort) and not receiving revascularization or not responding hemodynam-
ically to revascularization experienced a low risk of limb loss. We recommend
revising the hemodynamic criteria for CLI to better identify patients at high
risk for limb loss who require intervention to improve outcomes.Fig. Limp salvage by toe hemodynamic pressure groups.
Fig. Primary patency: Percutaneous transluminal angioplasty (PTA) vs
stent.Author Disclosures: R. Vallabhaneni: None; C. A. Kalbaugh: None; A.
Kouri: None;M. A. Farber: None;W. A. Marston: Consultant, Celgene.
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Primary Stent Placement Improves Patency After Endovascular
Treatment of Hepatic Artery Stenosis Following Liver Transplantation
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Introduction: Signiﬁcant hepatic artery stenosis (HAS) after ortho-
topic liver transplantation (OLT) can lead to thrombosis with subsequent
liver failure in 30% of patients. Although operative intervention or retrans-
plantation has been the traditional solution, endovascular therapy has
emerged as a less invasive treatment strategy. Prior smaller studies have
been conﬂicting in the relative efﬁcacy of percutaneous transluminal angio-
plasty (PTA) vs primary stent placement for HAS.
Methods: This was a single-center retrospective review of all endovas-
cular interventions for HAS after OLT during a 54-month period (August
2009-December 2013). Patients with ultrasound evidence of severe HAS
(peak systolic velocity >400 cm/s, resistive index of <0.5, tardus parvus
spectral abnormalities) underwent endovascular treatment with primary
stent placement or PTA. Outcomes calculated were technical success, pri-
mary and primary assisted patency rates, reinterventions, and complications.
Results: Sixty-two interventions for HAS were performed in 42 pa-
tients with a mean follow-up of 19.1 6 15.2 months. During the study
period, the rate of treated HAS was 6.4% (42 of 654). Primary technical suc-
cess was achieved in 95% (59 of 62) of cases. Initial treatment was with PTA
alone (n ¼ 16) or primary stent (n ¼ 26). Primary patency rates after initialstent placement were 91%, 81.3%, 77%, and 77% at 1, 6, 12, and 24 months,
respectively, and signiﬁcantly better (P ¼ .01) compared with 68.8%, 57.1%,
44% for initial PTA (Fig). There were 20 reinterventions in 14 patients
(eight stents, six PTAs) for recurrent HAS. The time to initial reintervention
in patients with PTA alone vs initial stent was 51 and 105.8 days, respec-
tively. Stent placement was required in 75% of reinterventions, of which
ﬁve drug-eluting stents were placed. Overall Kaplan-Meier primary patency
rates were 82%, 70%, 63%, and 50% at 1, 6, 12, and 24 months, respectively.
Overall primary-assisted patency was 96% at 12 months and 93% at
24 months. Major complications were one arterial rupture treated endovasc-
ularly and two hepatic artery dissections. Long-term risk of HAT in the
entire patient cohort was 4.8%.
Conclusions: In this series, which represents the largest reported
cohort of endovascular interventions for HAS to date, we demonstrate
that HAS after OLT can be treated endovascularly with high initial technical
success and excellent primary assisted patency. Initial stent placement signif-
icantly decreased the need for reintervention. Avoidance of HAT is possible
in >95% of patients with endovascular treatment and close follow-up.Author Disclosures: L. Le: None;W. Terral: None;N. Zea: None;H. A.
Bazan: None; T. A. Smith: None; G. E. Loss: None; E. Bluth: None;W.
C. Sternbergh: None.
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Introduction: Groin wound infection is a costly and morbid event af-
ter lower extremity revascularization. To date, a comprehensive and vali-
dated method for identifying patients who are at greatest risk for this
complication, and who might therefore beneﬁt from prophylactic muscle
ﬂap coverage of their initial groin incision, has yet to be developed.
Methods: Our retrospective analysis included all patients at a single
institution who underwent lower extremity revascularization in which a
groin incision was used from 2009 through 2012. Patients were randomly
divided into two groups matched for operative year and surgeon: a pilot
group, which was used to develop a predictive model for our primary
outcome, and a validation group, which was used to test that model. The
primary outcome for our analysis was groin wound infection requiring oper-
ative intervention. Potential predictor variables included patient age, sex,
year of operation, previous groin incision, use of thrombolytic agents,
concomitant amputation, body mass index, smoking status, diabetes melli-
tus, end-stage renal disease, malnutrition, preoperative wound, type of
conduit, level of distal target vessel, and emergency status of the index oper-
ation. Best-ﬁt model selection methods were used to evaluate all possible
combinations, interactions, and transformation of potential predictor vari-
ables from the pilot patient group. The resulting model with the lowest
Akaike information criterion was selected for testing using the validation pa-
tient group. A user-friendly computer program was developed that uses this
model to predict an individual patient’s risk of operative groin wound
infection.
Results: The study included 284 patients, 141 in the pilot group and
144 in the validation group, who underwent lower extremity revasculariza-
tion procedures. Seventeen patients (12.1%) from the pilot group developed
groin incision infection that required operation. The predictive model that
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of operative groin wound infection: previous groin incision, female gender,
body mass index, end-stage renal disease, malnutrition, and urgent/emer-
gency operation status. The C index of the resulting model was 0.845
and resulted in a correct classiﬁcation of 88.6% of patients. Subsequent
testing in the validation group (13.9% of whom sustained an operative groin
wound infection) yielded an accuracy of 86.1% for our predictive model. We
therefore developed a user-friendly computer program, which will be pub-
licly accessible, that can be used to calculate an individual patient’s risk of
developing operative groin wound infection after lower extremity revascu-
larization (Fig).
Conclusions: Our study is the ﬁrst known attempt to develop and
internally validate a statistical model that will accurately predict those pa-
tients who are likely to sustain an operative groin wound infection after
lower extremity revascularization.Fig. Risk calculator for postoperative groin wound infection.Author Disclosures: K. M. Bennett: None; H. Levinson: None; J. E.
Scarborough: None; C. K. Shortell: None.
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Introduction: Endothermal heat-induced thrombosis (EHIT) of the
common femoral vein or popliteal vein can occur after endovenous laser abla-
tion (EVLA) of the saphenous veins. We have previously reported an inci-
dence of 5.1% and identiﬁed that a vein diameter of $7.5 mm increased the
risk of EHIT after EVLA using an 810-nm wavelength laser. The impact of
laser wavelength on EHIT has not been previously evaluated, and we hypoth-
esized that the incidence of EHIT would depend on the laser wavelength.
Methods: We identiﬁed patients having EVLA in our ofﬁce from
2005-2014 with a 810-nm (hemoglobin-speciﬁc) or 1470-nm (water-spe-
ciﬁc) laser. We reviewed the records for age, gender, body mass index,
CEAP class, vein(s) treated, adjunctive phlebectomy, energy delivered,
EHIT (level $3) development, treatment and course. The Fisher exact test
and Pearson c2 were used to evaluate the association between deep venous
thrombosis (DVT) and the categoric variables. Logistic regression was used
to evaluate the relationship between DVT and the continuous variables.
Results: There were 1456 veins ablated in 1118 patients (775 female,
343 male). The great saphenous vein (GSV) was treated in 1337, the small
saphenous vein (SSV) in 77, and both were treated in 20 (22 procedures on
accessory veins were excluded). The CEAP class for these patients was 1 (0),
2 (618), 3 (521), 4 (148), 5 (50), 6 (95) and not recorded in 2. EHIT
occurred in 71 cases (4.95%), 68 after GSV ablation and three after SSV
ablation. The 810-nm laser was used in 1142, and 64 (5.6%) developed
EHIT. The 1470-nm laser was used in 292, with seven (2.4%) developing
EHIT (P ¼ .0229 by Fisher exact test). The average energy delivered to the
EHIT group (3475 6 1941 joules) was higher than for the non-EHIT
group (2866 6 1475 joules; P ¼ .0012). The average vein diameter was
higher in the EHIT group (9.3 6 3.9 mm) than in the non-EHIT group
(7.2 6 3.2 mm; P ¼ .0001). EHIT occurred in 55 of 836 patients
(6.17%) having simultaneous stab phlebectomy compared with 16 of 527
(2.95%) of patients having only EVLA (P ¼ .0057). Statistical analysisconﬁrmed there is signiﬁcant association between DVT and CEAP class
(P ¼ .0001). No differences were seen for age, body mass index, gender,
anticoagulation use, combined bilateral procedures, or simultaneous GSV
and SSV ablations between the two groups. EHIT in the femoral vein
was at level 3 (22), 4 (18), 5 (17), and 6 (14), and treatment for the
EHIT consisted of observation, anticoagulation, or antiplatelet therapy.
Duration of therapy was usually brief. No pulmonary emboli occurred in
any of these patients, and EHIT resolved completely in all.
Conclusions: This study shows that a water-speciﬁc laser ﬁber wave-
length (1470 nm) reduces the risk of EHIT compared with a hemoglobin-
speciﬁc wavelength (810 nm). It also demonstrates that CEAP class,
increased energy delivery, simultaneous phlebectomy, and increased vein
diameter are associated with increased risk of EHIT after EVLA.
Author Disclosures: W. P. Shutze: None; K. Kane: None; T. Fisher:
None; Y. Daoud: None; G. Lassiter: None; R. Lueking: None; E.
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Introduction: Ischemic steal syndrome (ISS) is a dreaded complica-
tion after hemodialysis access creation. Its management is complex and var-
ied, with most requiring surgical revision for correction of symptoms.
Revision using distal inﬂow (RUDI) has been described in small series for
the treatment of ISS. We present our experience with RUDI for the treat-
ment of ISS and pathologic high ﬂow (HF).
Methods: We retrospectively reviewed consecutive patients who un-
derwent RUDI for ISS from April 2010 to March 2014. Data collection
included demographics, medical histories, subsequent procedures, volume
ﬂows, access usage, limb salvage, and patient survival.
Results: We performed 32 RUDI procedures in 31 patients (18
women, 13 men). Indications for surgery were pathologic HF in 15 and
ISS in 21. Sixteen percent had prior plication for ISS or HF. Seventy-one
percent of patients had a history of diabetes, and 52% had a history of
atherosclerotic disease. Time to intervention from creation was 40 months
(range, 6-88 months). Accesses included one upper arm graft and 30
brachial artery-based ﬁstulas. Outﬂow included 26 cephalic veins and four
basilic veins. Distalization targets were 20 radial arteries, nine ulnar arteries,
and three distal brachial arteries. Mean ﬂow reduction was 994 mL/min.
Primary assisted patency at 1 year was 73%, and secondary patency was
88%. The RUDI in one patient was revised from a distal brachial to radial
inﬂow. A single access was ligated for continued heart failure after RUDI.
ISS symptom resolution was reported as complete in 81% and partial in 19%.
Conclusions: RUDI is an effective and lasting treatment of ISS and
HF and comparable to reported experiences with distal revascularization-in-
terval ligation, proximalization of the arterial inﬂow, and plication. Patient
selection is key for optimizing relief of symptoms and maintaining use of
the access.
Author Disclosures: T. M. Loh: None; M. E. Bennett: None; M. G.
Davies: None; E. K. Peden: Consultant, W. L. Gore and Associates
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Introduction: Initiatives to develop patient-centered approaches to
health care are a priority that may have profound effects on health care, partic-
ularlywithin value-basedpurchasing and risk-sharingmodels. Patient-centered
care requires more direct engagement of patients in their own care, including
treatment decisions. Patient participation in treatment selection for vascular
procedures has not been characterized, and the potential effects of greater pa-
tient involvement are unknown.We conducted a prospective study among pa-
tients undergoing vascular procedures to identify important sources of
information and characterize experienced vs desired decision-making roles.
Methods: Patients undergoing elective vascular procedures were
identiﬁed from an outpatient clinic and vascular laboratory. An instrument
consisting of multiple choice and open-ended response items related to pa-
tients’ roles in decision making, sources of information, and perceived treat-
ment success was administered. Diagnostic, demographic, and educational
data were collected. Descriptive statistics are presented as count (%) for
